603334.SH
丰倍生物
SSE · Healthcare · Biotechnology · CN
CNY 31.22
−4.44%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.6B | 3.2B | 1.9B | 1.7B | 1.7B |
| Cost of Revenue | 3.4B | 2.9B | 1.7B | 1.5B | 1.5B |
| Gross Profit | 259.2M | 258.9M | 227.4M | 241.0M | 231.6M |
| Operating Expenses | |||||
| R&D Expense | 70.3M | 68.2M | 53.6M | 58.6M | 51.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 39.4M | 37.5M | 29.1M | 35.1M | 25.4M |
| Selling & Marketing Expense | 20.9M | 20.8M | 21.8M | 21.8M | 15.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 154.8M | 145.9M | 110.8M | 123.7M | 95.5M |
| Cost and Expenses | 3.5B | 3.1B | 1.8B | 1.6B | 1.6B |
| Operating Income (EBIT) | 160.4M | 154.0M | 131.3M | 143.2M | 146.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 159.7M | 153.5M | 134.4M | 144.4M | 143.5M |
| Income Tax Expense | 14.9M | 13.0M | 10.6M | 14.7M | 10.1M |
| Bottom Line | |||||
| Net Income | 144.8M | 140.6M | 123.8M | 129.7M | 133.3M |
| Earnings from Cont. Ops | 144.8M | 140.5M | 123.8M | 129.7M | 133.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 144.8M | 140.6M | 123.8M | 129.7M | 133.3M |
| Per Share | |||||
| Basic EPS | CN¥1.23 | CN¥1.24 | CN¥1.15 | CN¥1.21 | CN¥1.26 |
| Diluted EPS | CN¥1.23 | CN¥1.24 | CN¥1.15 | CN¥1.21 | CN¥1.26 |
| Revenue Per Share | CN¥24.75 | CN¥27.97 | CN¥18.09 | CN¥16.12 | CN¥16.15 |
| Shares | |||||
| Basic Shares Outstanding | 146.0M | 113.4M | 107.7M | 107.2M | 105.8M |
| Diluted Shares Outstanding | 146.0M | 113.4M | 107.7M | 107.2M | 105.8M |
| Profitability Metrics | |||||
| EBITDA | — | 183.3M | 149.8M | 158.3M | 159.0M |
| D&A | — | 29.3M | 18.5M | 15.1M | 12.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026